T-cell lymphoma

[Bone Marrow Transplantation] Scientists report the outcome of 68 patients with advanced peripheral T-cell lymphoma receiving transplantation from haploidentical or from conventional donors. The four-year OS, PFS, 2-year cumulative incidence of relapse and 2-year GRFS was 75%, 70%, 21%, and 51%, respectively.

[Scientific Reports] By sequencing the exomes of the microdissected clusters of lymphoma cells from the epidermis and the dermis, scientists found that those microenvironments comprised different malignant clonotypes.

[Astex Pharmaceuticals, Inc] Astex Pharmaceuticals, Inc. announced that the FDA has granted orphan drug designation for the company’s novel, orally administered non-peptidomimetic antagonist of the cellular and X-linked inhibitors of apoptosis proteins, tolinapant, for the treatment of T-cell lymphoma.

[Acta Pharmacologica Sinica] Researchers showed that LW-213 dose-dependently inhibited human cutaneous T-cell lymphoma cell lines with IC50 values of around 10 μM, meanwhile it potently inhibited primary leukemia cells derived from peripheral blood of T-cell lymphoma patients.